These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33531064)

  • 1. Multiplexed single-cell mass cytometry reveals distinct inhibitory effects on intracellular phosphoproteins by midostaurin in combination with chemotherapy in AML cells.
    Rörby E; Adolfsson J; Hultin E; Gustafsson T; Lotfi K; Cammenga J; Jönsson JI
    Exp Hematol Oncol; 2021 Feb; 10(1):7. PubMed ID: 33531064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
    Kim M; Williams S
    Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
    Stansfield LC; Pollyea DA
    Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
    Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
    Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.
    Möllgård L; Deneberg S; Nahi H; Bengtzen S; Jonsson-Videsäter K; Fioretos T; Andersson A; Paul C; Lehmann S
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):439-48. PubMed ID: 17960382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.
    Yee KW; Schittenhelm M; O'Farrell AM; Town AR; McGreevey L; Bainbridge T; Cherrington JM; Heinrich MC
    Blood; 2004 Dec; 104(13):4202-9. PubMed ID: 15304385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of gilteritinib in combination with chemotherapy in preclinical models of
    Ueno Y; Mori M; Kamiyama Y; Saito R; Kaneko N; Isshiki E; Kuromitsu S; Takeuchi M
    Oncotarget; 2019 Apr; 10(26):2530-2545. PubMed ID: 31069015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy.
    Weisberg E; Sattler M; Manley PW; Griffin JD
    Onco Targets Ther; 2018; 11():175-182. PubMed ID: 29343975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin.
    Schittenhelm MM; Kampa KM; Yee KW; Heinrich MC
    Cell Cycle; 2009 Aug; 8(16):2621-30. PubMed ID: 19625780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
    Garcia JS; Percival ME
    Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Midostaurin: an emerging treatment for acute myeloid leukemia patients.
    Gallogly MM; Lazarus HM
    J Blood Med; 2016; 7():73-83. PubMed ID: 27186148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines.
    Furukawa Y; Vu HA; Akutsu M; Odgerel T; Izumi T; Tsunoda S; Matsuo Y; Kirito K; Sato Y; Mano H; Kano Y
    Leukemia; 2007 May; 21(5):1005-14. PubMed ID: 17330105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
    Williams CB; Kambhampati S; Fiskus W; Wick J; Dutreix C; Ganguly S; Aljitawi O; Reyes R; Fleming A; Abhyankar S; Bhalla KN; McGuirk JP
    Pharmacotherapy; 2013 Dec; 33(12):1341-52. PubMed ID: 23798029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases.
    Knapper S; Mills KI; Gilkes AF; Austin SJ; Walsh V; Burnett AK
    Blood; 2006 Nov; 108(10):3494-503. PubMed ID: 16868253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML.
    Waldeck S; Rassner M; Keye P; Follo M; Herchenbach D; Endres C; Charlet A; Andrieux G; Salzer U; Boerries M; Duyster J; von Bubnoff N
    Mol Oncol; 2020 Apr; 14(4):779-794. PubMed ID: 31955503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia.
    Zhang X; Li B; Yu J; Dahlström J; Tran AN; Björkholm M; Xu D
    Ann Hematol; 2018 Jan; 97(1):63-72. PubMed ID: 29080039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.
    Seedhouse CH; Hunter HM; Lloyd-Lewis B; Massip AM; Pallis M; Carter GI; Grundy M; Shang S; Russell NH
    Leukemia; 2006 Dec; 20(12):2130-6. PubMed ID: 17066094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
    Doshi KA; Trotta R; Natarajan K; Rassool FV; Tron AE; Huszar D; Perrotti D; Baer MR
    Oncotarget; 2016 Jul; 7(30):48280-48295. PubMed ID: 27374090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.